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The proteasome inhibitor bortezomib (Bz) has been approved for treatment of myeloma.
Recent studies demonstrate high response rates when Bz is used in combination with oral melphalan and prednisone 5 . While the mechanism of action is not completely understood, Bz senstitizes myeloma cells, in vitro, to DNA-damaging agents such as melphalan, and overcomes chemoresistance 6 . It also acts upon the bone marrow microenvironment, inhibiting nuclear factor-κB activation in bone marrow stromal cells, leading to a reduction in interleukin-6 production and enhanced apoptosis of myeloma cells 7 . Recently, Bz has been incorporated into HDM conditioning for SCT in myeloma 8 . Pre-clinical and phase I/II data have suggested that the optimal timing of administration of a single dose of bortezomib is 24 hours after melphalan 6, 9 .
Because hematologic CR is a critical determinant of treatment outcome following HDM/SCT, we hypothesized that the addition of Bz to HDM/SCT could increase hematologic Hematologic responses occurred in 89% of treated subjects (n=8/9), of which 6 (67%)
were hematologic CRs. Thus, by intention-to-treat, 80% (n=8/10) had a hematologic response to months from the enrollment on study.
In conclusion, this pilot study demonstrates that the addition of Bz to the conditioning regimen for HDM/SCT is feasible and well-tolerated by patients with AL amyloidosis. The combination resulted in no increase in adverse events over those typically seen with HDM alone.
Furthermore, the combination produced a high rate of hematologic and organ responses.
Although this pilot study is small in highly select patients, the CR rate of 67% of treated patients compares favorably with that of 40% seen in prior series using melphalan alone for conditioning 5 . This suggests that there may be additive or synergistic activity of Bz and melphalan, due to the activity of Bz as a chemosensitizer 6 and its effect on the bone marrow microenvironment 7 . We plan a second clinical trial using Bz for initial induction therapy as well as incorporating it into the conditioning regimen. Based upon the results of these two studies, the regimen with superior phase II results will be compared to a standard melphalan-based SCT in a randomized phase III study, with the goal of determining whether the addition of Bz leads to a higher rate of hematologic and clinical responses, and better progression-free and overall survival.
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Figure Legends:
Renal response with improvement in urine protein excretion at 1 year after Bz-HDM/SCT
